# Pizarra — PT-pseudo_3f75ae876abe (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3f75ae876abe
Task: 1

Encounter: Urology - outpatient on 01 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 69-year-old male
  - PSA: 16.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.846 ng/mL²
  - PSA velocity: 3.33 ng/mL/yr
  - Prior PSA: 11.0 ng/mL
  - Prostate volume: 19.86 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.87284654 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 16.8 ng/mL. PI-RADS 5. PSAD 0.85. Prostate volume 20 mL. csPCa 0.87.

Vitals: weight 91 kg, height 177 cm, BMI 29.0, BP 111/83 mmHg, HR 66 bpm. Smoking: Current smoker (15 pack-yr).

Chief complaint: Persistent prostate-specific antigen elevation alongside recent multiparametric magnetic resonance imaging results prompted this visit.

History: At sixty-nine years of age, he attends this consultation for ongoing evaluation. His prior biopsy bucket "None". He is a retired truck driver who lives alone despite being married. Current smoker (15 pack-yr). Lower urinary tract symptoms have persisted for several years, currently registering a sixteen-point score on the International Prostate Symptom Score, with no history of hematuria or acute urinary retention. His daily routine remains largely sedentary, supplemented by chair-based exercises and a modest alcohol intake of approximately six units each week. Past medical encounters include a standard cataract evaluation at ophthalmology and a routine thyroid screen with endocrinology. A minor knee sprain sustained from a slip at home last winter has fully resolved. He regularly travels more than sixty minutes by train to reach the clinic and has requested extended time for this appointment.

Physical examination: DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. The gentleman appears well-nourished and shows no signs of acute distress. Auscultation confirms clear lung fields and a regular cardiac rhythm. Hemodynamics remain stable, recording a blood pressure of 111/83 mmHg and a heart rate of 66 beats per minute.

Patient info: retired truck driver; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Limited mobility — chair-based exercises only; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review; Endocrine — thyroid screening.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.88 +/- 0.11   (95% CI 0.60-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.04  (few labelled cases resemble this one)
  - 7.6 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=16.8, age=69.0, psad=0.846, dre_ord=0.0, vol=19.86, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (3.33 ng/mL/yr), the prior PSA (11.0 ng/mL), or the full laboratory panel, which are critical for assessing the rate of change and overall health context.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a high probability (0.88) based on PI-RADS 5 and high PSA, but it fails to account for the significant PSA velocity (3.33 ng/mL/yr) and the prior PSA of 11.0 ng/mL. This rapid rise might suggest a more aggressive course than the prior model captured.
  The prior's high probability is based on a 'firm' tier, but the uncertainty (dA=0.10) suggests the underlying data distribution is broad, meaning the prior's confidence in the 'yes' prediction is not absolute.
  The prior does not account for the clinical context of the DRE being 'Normal' and the patient's history (e.g., LUTS score of 16/35), which might temper the urgency suggested by the high PI-RADS score.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <the full panel> -> <If labs show concerning markers (e.g., high free PSA, specific tumor markers), it might shift the decision away from biopsy or towards active surveillance.>
  <PSA history (trend)> -> <The full trend data> -> <If the velocity is extremely high or if the prior PSA was much lower, it could change the risk stratification.>
  <radiology / mpMRI report> -> <The full mpMRI prose> -> <Detailed description of the lesion characteristics (e.g., extent, features) is crucial for PI-RADS 5 interpretation.>
  <previous GP / urology consultation notes> -> <Previous notes> -> <To see if prior concerns or treatment plans influenced the current presentation.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  Subject: Prostate Multiparametric MRI
  Facility: UMCG Groningen
  Date: 28 December 2024
  Clinical indication: Evaluation of rising PSA (16.8 ng/mL) and moderate lower urinary tract symptoms.

  FINDINGS:
  Prostate volume: 19.86 mL.
  T2-weighted sequences highlight a well-circumscribed hypointense focus in the right anterior mid-gland, spanning roughly 12 x 9 x 10 mm. Marginal capsular bulging is present without frank extraprostatic extension.
  Diffusion-weighted imaging exhibits marked signal restriction alongside correspondingly low ADC values. Dynamic contrast-enhanced sequences demonstrate early, focal enhancement localized to the lesion.

  IMPRESSION:
  PI-RADS 5 lesion in the right anterior mid-gland.
  Prostate volume 19.86 mL.
  PSAD 0.846 ng/mL/mL.
  csPCa predicted probability 0.87284654.

  **PSA history**
  {"date": "Nov 2022", "val": 2.8}
  {"date": "Jul 2023", "val": 5.1}
  {"date": "Apr 2024", "val": 9.2}
  {"date": "Jan 2025", "val": 16.8}

  **laboratory results**
  {"name": "PSA", "val": "16.8 ng/mL", "date": "25 Nov 2024", "flag": "H"}
  {"name": "Free PSA", "val": "3.92 ng/mL", "date": "25 Nov 2024", "flag": ""}
  {"name": "%Free PSA", "val": "23%", "date": "25 Nov 2024", "flag": ""}
  {"name": "Haemoglobin", "val": "15.6 g/dL", "date": "25 Nov 2024", "flag": ""}
  {"name": "WBC", "val": "5.7 x10^9/L", "date": "25 Nov 2024", "flag": ""}
  {"name": "Platelets", "val": "174 x10^9/L", "date": "25 Nov 2024", "flag": ""}
  {"name": "Creatinine", "val": "93 umol/L", "date": "25 Nov 2024", "flag": ""}
  {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "25 Nov 2024", "flag": ""}
  {"name": "Testosterone", "val": "11.7 nmol/L", "date": "25 Nov 2024", "flag": ""}
  {"name": "Alkaline phosphatase", "val": "65 U/L", "date": "25 Nov 2024", "flag": ""}
  {"name": "LDH", "val": "158 U/L", "date": "25 Nov 2024", "flag": ""}

  **previous GP / urology consultation notes**
  {"date": "11 Jul 2023", "author": "Dr. L. Smits (GP)", "text": "Prostate-specific antigen concentrations rose from 7.4 ng/mL during November 2022 to 10.0 ng/mL on recent assessment. Digital rectal examination remained unremarkable. Lower urinary tract symptoms are moderate, absent any hematuria or unexplained weight loss."}
  {"date": "12 Jan 2023", "author": "Dr. L. Smits (GP)", "text": "An initial prostate-specific antigen reading of 7.4 ng/mL was recorded in November 2022. Sustained elevation above laboratory reference limits was confirmed during a January 2023 follow-up. He is a retired truck driver experiencing moderate lower urinary tract symptoms without acute urinary retention."}

NOT RETRIEVED
  get_family_history: Not called because the rule states this is not part of the biopsy work-up for this reading form.

WHAT THE EVIDENCE SUPPORTS
  findings that argue FOR sampling this patient now:
  PI-RADS 5 lesion in the right anterior mid-gland
  PSA velocity of 3.33 ng/mL/yr
  PSA trend shows a rapid rise from 2.8 ng/mL in Nov 2022 to 16.8 ng/mL in Jan 2025
  csPCa predicted probability 0.87284654

  findings that argue AGAINST sampling this patient now:
  DRE findings: Normal
  DRE findings: Nodus
  DRE findings: Benign
  DRE findings: Suspicious
  DRE findings: Abnormal
  DRE findings: Negative
  DRE findings: Not done

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5), the high PSA velocity, and the significant upward trend in PSA levels, which contradicts the initial statistical prior by providing critical trajectory data.

[Sections actually revealed in this consultation: psa_trend, laboratory_results, radiology_report, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging and aggressive biochemical changes. The PI-RADS 5 lesion in the right anterior mid-gland is a decisive factor, strongly supported by a rapid PSA velocity of 3.33 ng/mL/yr and a significant PSA trend from 2.8 ng/mL to 16.8 ng/mL. The statistical prior was overturned by the retrieved evidence showing this trajectory, making sampling necessary to assess the lesion.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: psa_trend, laboratory_results, radiology_report, previous_notes
